NASDAQ
NKTX

Nkarta Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Nkarta Inc Stock Price

Vitals

Today's Low:
$1.6
Today's High:
$1.81
Open Price:
$1.72
52W Low:
$1.55
52W High:
$14.57
Prev. Close:
$1.71
Volume:
678363

Company Statistics

Market Cap.:
$86.83 million
Book Value:
6.482
Revenue TTM:
$385
Operating Margin TTM:
0%
Gross Profit TTM:
$-36220000
Profit Margin:
0%
Return on Assets TTM:
-18.28%
Return on Equity TTM:
-33.84%

Company Profile

Nkarta Inc had its IPO on 2020-07-10 under the ticker symbol NKTX.

The company operates in the Healthcare sector and Biotechnology industry. Nkarta Inc has a staff strength of 169 employees.

Stock update

Shares of Nkarta Inc opened at $1.72 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.6 - $1.81, and closed at $1.65.

This is a -3.51% slip from the previous day's closing price.

A total volume of 678,363 shares were traded at the close of the day’s session.

In the last one week, shares of Nkarta Inc have slipped by -6.78%.

Nkarta Inc's Key Ratios

Nkarta Inc has a market cap of $86.83 million, indicating a price to book ratio of 0.9096 and a price to sales ratio of 999999.9999.

In the last 12-months Nkarta Inc’s revenue was $385 with a gross profit of $-36220000 and an EBITDA of $-133386000. The EBITDA ratio measures Nkarta Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Nkarta Inc’s operating margin was 0% while its return on assets stood at -18.28% with a return of equity of -33.84%.

In Q2, Nkarta Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Nkarta Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-2.54 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Nkarta Inc’s profitability.

Nkarta Inc stock is trading at a EV to sales ratio of 999999.9999 and a EV to EBITDA ratio of -0.52. Its price to sales ratio in the trailing 12-months stood at 999999.9999.

Nkarta Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$429.04 million
Total Liabilities
$26.61 million
Operating Cash Flow
$0
Capital Expenditure
$10.33 million
Dividend Payout Ratio
0%

Nkarta Inc ended 2024 with $429.04 million in total assets and $0 in total liabilities. Its intangible assets were valued at $429.04 million while shareholder equity stood at $317.98 million.

Nkarta Inc ended 2024 with $0 in deferred long-term liabilities, $26.61 million in other current liabilities, 5000.00 in common stock, $-382035000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $29.12 million and cash and short-term investments were $280.75 million. The company’s total short-term debt was $6,050,000 while long-term debt stood at $0.

Nkarta Inc’s total current assets stands at $286.74 million while long-term investments were $18.73 million and short-term investments were $251.64 million. Its net receivables were $0 compared to accounts payable of $3.01 million and inventory worth $0.

In 2024, Nkarta Inc's operating cash flow was $0 while its capital expenditure stood at $10.33 million.

Comparatively, Nkarta Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.65
52-Week High
$14.57
52-Week Low
$1.55
Analyst Target Price
$19.63

Nkarta Inc stock is currently trading at $1.65 per share. It touched a 52-week high of $14.57 and a 52-week low of $14.57. Analysts tracking the stock have a 12-month average target price of $19.63.

Its 50-day moving average was $1.97 and 200-day moving average was $4.26 The short ratio stood at 7.37 indicating a short percent outstanding of 0%.

Around 704.9% of the company’s stock are held by insiders while 8817.6% are held by institutions.

Frequently Asked Questions About Nkarta Inc

The stock symbol (also called stock or share ticker) of Nkarta Inc is NKTX

The IPO of Nkarta Inc took place on 2020-07-10

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$32.29
0.03
+0.09%
$70.1
-2.54
-3.5%
$17.43
0.37
+2.17%
$12.01
0.35
+3%
$4.42
-0.01
-0.23%
$3348.7
-111.35
-3.22%
$167.75
-8.8
-4.98%
$113.25
0.5
+0.44%
$10.11
0
+0.05%
JSW Energy Limited (JSWENERGY)
$397.45
-34.05
-7.89%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company’s approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Address

6000 Shoreline Court, South San Francisco, CA, United States, 94080